A Sponsor Un-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat, Ascending Doses of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs GSK 2798745 (Primary)
- Indications Pulmonary oedema
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 20 Jan 2017 Status changed from recruiting to completed.
- 22 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.
- 22 Nov 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2016.